Sort
10,766 grants matching “checkpoint inhibitor”
Project 2 - Joshua Hood, PhD
$203,853Joshua L. Hood · University Of Louisville · P20 · FY2024 · GM
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY
$203,619University Of Texas Md Anderson Can Ctr · R01 · FY2002 · CA
Targeting tissue factor as a novel oncotarget for immunotherapy of triple negative breast cancer
$203,580Zhiwei Hu · Ohio State University · R21 · FY2018 · CA
Targeting metabolism in leukemic stem cells
$203,580Cheng-Kui Qu · Emory University · R21 · FY2015 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$203,550Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2021 · CA
Development of a new treatment modality for melanoma brain metastases - Resubmission - 1
$203,400Iman Osman · New York University School Of Medicine · R21 · FY2015 · CA
Role of probiotic Lactobacillus reuteri in orchestrating systemic anti-tumor immunity
$203,352Marlies Meisel · University Of Pittsburgh At Pittsburgh · R21 · FY2023 · CA
ATM Regulation via PP2A and Ceramide
$203,000Helen H Chun · California State Univ-Dominguez Hills · R15 · FY2007 · GM
The role of CADM1 in malignant melanoma
$202,939Edward Hartsough · Drexel University · R00 · FY2019 · CA
Mitotic Regulation by the ERRbeta2 Splice Variant
$202,928Rebecca B Riggins · Georgetown University · R21 · FY2015 · CA
Novel injectable resiquimod formulation for treatment of metastatic cancers
$202,854Yen T Wang · Curebiotech, Inc. · R43 · FY2017 · CA
Development of IG7 as an enhancer of anti-PD-1 cancer immunotherapy
$202,500Chunwan Lu · Chemedimmune, Inc. · R43 · FY2018 · CA
CCSG Supplement: Early-stage Surgeon Scientist Program (ESSP) - Chibawanye Ene
$202,500Giulio Francesco Draetta · University Of Tx Md Anderson Can Ctr · P30 · FY2023 · CA
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
$202,500David Rinsey Bickers · Columbia University Health Sciences · R21 · FY2020 · TR
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
$202,439Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R21 · FY2017 · CA
Mechanisms of CD4 autoreactivity after checkpoint inhibition
$202,320Terri M. Laufer · University Of Pennsylvania · R21 · FY2025 · AI
Abrogating a survival pathway in early colon cancer cells
$202,275Nan Gao · Rutgers The State Univ Of Nj Newark · R21 · FY2013 · CA
In vivo anti-PD1 gene therapy
$202,112Andre Michael Lieber · University Of Washington · R21 · FY2017 · CA
Target validation of CD206 activators
$201,957Juan Marugan · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
An RNA:DNA intermediate of LINE-1 retrotransposition - a novel trigger of cytotoxicity
$201,913Alex Bortvin · Carnegie Institution Of Washington, D.C. · R21 · FY2018 · HD
Development of Methods for Precise MR-guided Hyperthermia Delivery for Targeted Cancer Therapies
$201,875Eugene Ozhinsky · University Of California, San Francisco · R21 · FY2021 · EB
Adipokine Signaling in Melanoma: Unmasking the Obesity Paradox.
$201,875Thomas P Loughran · University Of Virginia · P30 · FY2024 · CA
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
$201,871Sean S Park · Mayo Clinic Rochester · R21 · FY2021 · CA
Structural studies of molecular cancer targets and drug development
$201,856David S Waugh · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Arginine Regulates T Cell Signal Transduction & Function
$201,658Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2007 · CA